Clinical Trial Update: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) [Phase 1]

View source ↗

Summary

Phase 1 trial update of favezelimab (MK-4280) as monotherapy or in combination with pembrolizumab (MK-3475), with or without chemotherapy or lenvatinib (MK-7902…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Favezelimab (MK-4280) (favezelimab)
• Lenvatinib (MK-7902) (lenvatinib)
• Pembrolizumab (MK-3475) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2025-05-30